CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Grant or award Director acquired 122,950 shares (grant or award)
- 4 Open-market sale Director sold 11,200 shares at $2.34 ($26,181)
- 8-K Event Material agreement
- 144 Insider Sale of Securities
- 4 Open-market buy Director bought 1,724,137 shares at $2.90 ($4,999,997)
- 4 Grant or award CHIEF FINANCIAL OFFICER acquired 344,828 shares (grant or award)
- 4 Grant or award President and CEO acquired 344,828 shares (grant or award)
- 8-K Event Other events
- 424B5 Offering Prospectus
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- EFFECT Other Notice of Effectiveness
- 4 Shares withheld for taxes Chief Technical Officer gave up 17,360 shares (to pay taxes)
- CORRESP Other Correspondence Between Filers and SEC Staff
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 144 Insider Sale of Securities
- UPLOAD Other SEC-generated Letter
- 4 Shares withheld for taxes President and CEO gave up 53,393 shares (to pay taxes)
Page 10 of 30 · 587 filings